drugset

drugset / Trial / NCT00284076

L-Arginine in the Treatment of Peripheral Arterial Disease

NCT00284076 ↗

Completed Stanford University National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedTreatment

Summary

To assess the effects of L-arginine upon functional status (treadmill exercise testing; quality of life) and limb blood (by mercury strain gauge plethysmography) in peripheral arterial disease.

Timeline

Start: 2000-02
Primary completion: 2006-07
Completion: 2006-07

Publications

Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, Kielstein J, Cooke JP. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med. 2010 Aug;15(4):267-74. doi: 10.1177/1358863X10364552. Epub 2010 May 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	L-arginine	Small molecule	0 g	Oral
Subject	L-arginine	Small molecule	3 g	Oral
Subject	L-arginine	Small molecule	6 g	Oral
Subject	L-arginine	Small molecule	9 g	Oral

Indications